Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915081 | 1.00 | KDM4E (0.51) | KDM4EHTTL3MBTL1POLBLCK | |
| SCHEMBL1707143 | 0.86 | LCK (0.58) | KDM4EHTTL3MBTL1POLBLCK | |
| SCHEMBL17653164 | 0.86 | KDM4E (0.51) | KDM4EHTTL3MBTL1POLBLCK | |
| SCHEMBL705665 | 0.85 | KDM4E (0.69) | KDM4EHTTL3MBTL1POLBLCK | |
| SCHEMBL30870738 | 0.85 | KDM4E (0.69) | KDM4EHTTL3MBTL1POLBLCK | |
| SCHEMBL856563 | 0.84 | KDM4E (0.74) | KDM4EL3MBTL1POLBLCKFYN | |
| SCHEMBL16462717 | 0.83 | CYP3A4 (0.50) | KDM4EHTTLCKFYNCYP1A2 | |
| SCHEMBL24792076 | 0.81 | KDM4E (0.51) | KDM4EL3MBTL1POLBLCKFYN | |
| SCHEMBL17653373 | 0.81 | HMGCR (0.50) | KDM4EL3MBTL1POLBLCKFYN | |
| SCHEMBL1580024 | 0.81 | TSHR (0.53) | KDM4ECYP1A2HTR1AADRA2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-4322947-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF RIP2 KINASE, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-02-21 | — | — | EP | disclosed |
| EP-3558979-B1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-2984088-B1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2018115380-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9757382-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 376/4885HTT 2307/4885L3MBTL1 2616/4885 |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | KDM4E 1337/4885HTT 3456/4885L3MBTL1 4366/4885 |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 386/4885HTT 2260/4885L3MBTL1 2629/4885 |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | KDM4E 1536/4885HTT 3291/4885L3MBTL1 1727/4885 |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | KDM4E 386/4885HTT 2260/4885L3MBTL1 2629/4885 |
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | RIPK2, RIPK1, RIPK3 | KDM4E 2979/4885HTT 2043/4885L3MBTL1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.